Blog | HemaCare

Improving the Efficiency of Clinical Gene Therapy

Jul 23, 2018 10:09:00 AM / by Nancy Andon, MSc posted in engraftment, Gene Therapy, gene editing, hematopoietic stem cells, progenitor cells

0 Comments

An independent study [1] cites using HemaCare-sourced human cord blood, bone marrow, and mobilized peripheral blood as the starting material in a new strategy for more efficient genetic modification of human stem cells.

The study is based at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Researchers there have been looking into ways to make gene transduction, which is used to introduce an edited copy of a human gene into stem cells, more efficient. The new strategy is part of their goal to improve the potency and long-term engraftment of stem cells used for gene therapy in the clinic.

Read More

CD34+ or CD34−: Does it Really Matter?

Sep 26, 2016 1:13:22 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone Marrow, bone marrow stem cells, CD34, progenitor cells, Stem Cells

0 Comments

CD34 is a glycoprotein located in cell membranes, and was initially found to be present in hematopoietic stem and progenitor cells. CD34 is a commonly used marker for stem cells; however, there have been some experiments in the past that questioned whether CD34 is in fact a marker for these cells because some progenitor cells do not have CD34 (CD34‒), yet can produce CD34+ stem cells. Studies over the years show that CD34+ cells provide the hematopoietic activity (blood cell formation) in bone marrow and the development of specialized blood cells types (differentiation). Transplantation of patients with bone marrow that has a higher concentration of CD34+ cells is associated with faster engraftment (growth of healthy blood stem cells) and less related complications.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts